IMPEL NEUROPHARMA INC (IMPL) is a publicly traded company in the Unknown sector. Across all available filings, 11 corporate insiders have executed 52 transactions totaling $53.3M, demonstrating a bullish sentiment with $53.2M in net insider flow. The most recent transaction on Dec 19, 2023 involved a sale of 208,657 shares valued at $16.7K.
No significant insider buying has been recorded for IMPL in the recent period.
No significant insider selling has been recorded for IMPL in the recent period.
Based on recent SEC filings, insider sentiment for IMPL is bullish with an Insider Alignment Score of 100/100 and a net flow of $53.2M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at IMPEL NEUROPHARMA INC (IMPL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 11 insiders are actively trading IMPL stock, having executed 52 transactions in the past 90 days. The most active insider is Henry R. Kravis (Executive), who has made 3 transactions totaling $18.1M.
Get notified when executives and directors at IMPL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Dec 19, 2023 | Surplus Fund Viii, L.p. Vivo Capital | Executive | Sale | 208,657 | $0.08 | $16.7K | |
| Dec 19, 2023 | Surplus Fund Viii, L.p. Vivo Capital | Executive | Sale | 28,632 | $0.08 | $2.3K | |
| Dec 18, 2023 | Surplus Fund Viii, L.p. Vivo Capital | Executive | Sale | 28,682 | $0.11 | $3.2K | |
| Dec 18, 2023 | Surplus Fund Viii, L.p. Vivo Capital | Executive | Sale | 209,029 | $0.11 | $23.0K | |
| Dec 15, 2023 | Surplus Fund Viii, L.p. Vivo Capital | Executive | Sale | 87,934 | $0.29 | $25.5K | |
| Dec 15, 2023 | Surplus Fund Viii, L.p. Vivo Capital | Executive | Sale | 12,066 | $0.29 | $3.5K | |
| Dec 31, 2022 | Harold Leaman John | Executive | Payment | 3,627 | $3.75 | $13.6K | |
| Dec 31, 2022 | Harold Leaman John | Executive | Option Exercise | 10,571 | $N/A | $0 | |
| Mar 29, 2022 | B. Shrewsbury Stephen | Executive | Option Exercise | 24,606 | $1.97 | $48.5K | |
| Dec 22, 2021 | Hoekman John | Executive | Option Exercise | 20,000 | $1.64 | $32.8K | |
| Nov 19, 2021 | S. Nelson Timothy | Executive | Purchase | 10,000 | $10.76 | $107.6K | |
| Sep 21, 2021 | B. Shrewsbury Stephen | Executive | Option Exercise | 14,780 | $1.97 | $29.1K | |
| Sep 21, 2021 | B. Shrewsbury Stephen | Executive | Option Exercise | 4,650 | $2.46 | $11.4K | |
| Sep 21, 2021 | B. Shrewsbury Stephen | Executive | Option Exercise | 53,954 | $2.95 | $159.2K | |
| Aug 18, 2021 | Adams Adrian | Executive | Purchase | 600 | $15.89 | $9.5K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 10 | $53.3M | 89.8% |
Conversion(C) | 25 | $4.1M | 6.9% |
Other(J) | 4 | $1.6M | 2.7% |
Exercise(M) | 6 | $281.0K | 0.5% |
Sale(S) | 6 | $74.1K | 0.1% |
Payment(F) | 1 | $13.6K | 0.0% |
Insiders at IMPEL NEUROPHARMA INC are accumulating shares at an accelerated pace. With 11 insiders making 52 transactions totaling $53.3M in purchases versus $74.1K in sales, the net buying activity of $53.2M signals strong executive confidence. Henry R. Kravis (Executive) leads the buying activity with $18.1M in transactions across all time.